Patritumab clinical trials
Also written U3-1287.
How each study uses patritumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Daiichi Sankyo (6) · U3 Pharma GmbH (1) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Cetuximab (1) · Copper Cu 64-DOTA-Anti-HER3 Monoclonal Antibody U3-1287 (1)
Studies
Open first, then newest update. How each study uses patritumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung CancerCompletedPhase 1/2Daiichi SankyoNCT01211483Written as U3-1287
- Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )TerminatedPhase 2Daiichi SankyoNCT02633800Written as Patritumab
- Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck CancerCompletedPhase 1Daiichi SankyoNCT02350712Written as Patritumab
- Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)TerminatedPhase 3Daiichi SankyoNCT02134015Written as Patritumab
- Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)TerminatedPhase 1/2Daiichi SankyoNCT01512199Written as U3-1287
- Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)CompletedPhase 1Daiichi SankyoNCT01957280Written as patritumab
- Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid TumorsTerminatedPhase 1Washington University School of MedicineNCT01479023Written as U3-1287 (unlabeled)
- Phase I Study of U3P1287/01, Including Patients With Advanced Solid TumorsCompletedPhase 1U3 Pharma GmbHNCT00730470Written as U3-1287 (AMG888)
Given beside what is tested · 1 — patritumab is usual care or a partner of the new treatment
Codes
What other systems call patritumab · ClinicalTrials.gg INT006405
- MeSH (NLM) C585471patritumabOne source NLM
- UNII (FDA) 86780VJI1QPATRITUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7148077PatritumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78853PatritumabOne source FDA
- DrugBank DB12090One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585471 | patritumab | One source NLM |
| UNII (FDA) | 86780VJI1Q | PATRITUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7148077 | Patritumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78853 | Patritumab | One source FDA |
| DrugBank | DB12090 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.